Preprint / Version 1

Favipiravir as RNA Polymerase Dependent (Rdrp) in COVID-19



Coronavirus disease 2019 or Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a new virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This disease became a pandemic and is being discussed around world because it has significant consequences on public health and global economy. Favipiravir is an anti-viral agent that selectively and potently inhibits RNA-dependent RNA polymerase (RdRp) from RNA viruses. Favipiravir was discovered through a screening list of chemicals with anti-viral activity against influenza virus by Toyama Chemical Coorperation. Use of Favipiravir in clinical trials has shown radiological improvement in lung CT scans and a faster viral clearance time than or antivirals.


Favirpiravir, anitiviral, RdRp, COVID-19


Download data is not yet available.


World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 70 March - April 2020.

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 March - April 2020.

Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan, dkk. Coronavirus Disease 2019: Tinjauan literatur terkini coronavirus disease 2019: Review of current literatures. Jurnal Prnyakit Dalam Indonesia. Jakarta. Maret 2020;Vol 7:1: p45-67.

Wu Y-C, Chen C-S, Chan Y-J. The outbreak of CoVID-19: An overview. . J Chin Med Assoc. Taiwan, ROC. February, 2020.

Lu C-C, Chen M-Y, Chang Y-L. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. Taiwan. March 2020.

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Maret 2020. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.

Kementerian Kesehatan Republik Indonesia. Info Infeksi Emerging Kementerian Kesehatan RI [Internet]. 2020 Available from: https://

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and treatment coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463. doi:10.2183/pjab.93.027

Riedel S, Morse S, Mietzner T, Miller S. Jawetz, Melnick, & Adelberg’s Medical Microbiology. 28th ed. New York: McGraw- Hill Education/Medical; 2019. p.617-22.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.

Shiraki K, Daikouku T. Favipiravir, an antiinfluenza drug against life- threatening RNA virus infections. Pharmacol Ther. 2020.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; published online March 2. DOI: 10.1038/s41564-020-0695-z

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; published online March 3. DOI: 10.1016/j.jaut.2020.102433.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin- converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; published online March 3. DOI: 10.1007/s00134-020- 05985-9

Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.

Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020; published online March 6. DOI: 10.1002/ jmv.25749.

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.

Bruslind L. The Viruses in General Microbiology. Ed 1st. Oregon State University. USA. 2020 ;8

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19.The New England Journal of Medicine. March. 2020; 19:382;p1787-99

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. Vol 24.p91-98

Bergmann CC, et al. Coronavirus infection of the central nervous system; host-virus standoff. Nature review Microbiology 4. 2006. p121-132

Masters PS. The Molecular biology of coronaviruses. Virus researches. 2006. 66:p193-292

Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome- associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A. 2004;101(12):4240-5.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;p1-24. published online March 12. DOI: 10.1093/ cid/ciaa248.

Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;p102-8. published online March 5. DOI: 10.1016/j.jpha.2020.03.001Fan YY, Huang ZT, Li L, Wu MH, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol. 2009;154(7):1093-9.

Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; published online March 16. DOI: 10.1038/s41591- 020-0819-2.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Centers for Disease Control and Prevention. People who are at higher risk. 2020.

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020

Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020 February 7 (Epub ahead of print).

Hussain A, Kaler J, Tabrez E, Tabrez S, Tabrez SSM. Novel COVID-19: A comprehensive review of transmission, manifestation, and pathogenesis. The Cureus Journa Medical Science. 2020. 12(5).

Adhikari, S., Meng, S., Wu, Y. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 9. 2020

Soeroto AY, dkk. Kompedium Diagnostik dan pengobatan COVID-19 (INTERIM) Perhimpunan Respirologi Indonesia (PERPARI). Indonesia Journal Chest. 2020. Vol 7;1.p17-49

Burhan E, dkk. Protokol tatalaksana COVID-19. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Jakarta. 2020

Smith T, Bushek J, Prosser T. COVID-19 drug therapy. 2020

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al.Role of lopinavir/ritonavir in the trestment of SARS : initial virological and clinical findings. Thorax. 2004; 59(3):p252-6

Yao TT, Qian JD, Zhu WY, et al. A systematic review of lopinavir/ritonavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for COVID-19treatment option. J Med Virol. 2020

Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. 2020

Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. Juli, 2020. 26:7: p917-21

Ning Q and Han M. A. Prospective/retrospective, randomized controlled Clinical Study of Antiviral therapy in the 2019-nCoV Pneumonia. Feb 2020.

Kongsaedao S. Various Combination of Protease Inhibitors, Oseltamivir, favipiravir, and Chloroquin for treatment of COVID19: A Randomized control trial (THDMS-COVID19). March 2020. NCT04303299.

Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed

Du YX, Chen X-P. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clinical pharmacology & therapeutics. 2020.

Shannon A, Selisko B, Le NTT, Huchting J, Touret F, Piorkowski G, et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. May,2020

Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. (2013) The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5?-triphosphate towards influenza A virus polymerase. PLoS One 8, e68347.

Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., Shiraki K. (2002) In vitro and in vivo activities of anti-influenza virus compound T- 705. Antimicrob. Agents Chemother.46, 977–981.

Baranovich T., Wong S.S., Armstrong J., Marjuki H., Webby R.J., Webster R.G., Govorkova E.A. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013. 87, 3741–3751

Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013. 100, 446–454.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, dkk. COVID-19 infection: the perspectives on immune responses. Cell Death & Differentiation. Mei. 2020;27(5):1451-4.

Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q.M., Ozawa, M,et al. T-705 (favipiravir) activity against lethal H5N1 513 influenza A viruses. Proc. Natl. Acad. Sci. USA,2010.107, 882–887.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open label conrol study. Enginering. 2020:p1-7.

Pilkington V, Pepperell T, Hill A. A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?. Journal of Virus Eradication. London. 2020:6;p45-51.